SMi Group announces the return of its 11th annual Pharmaceutical Logistics conference to London on the 18th- 19th May 2017. Outsourcing logistics tasks to third parties has been observed as an emerging trend in the global market and it is only expected to gain momentum in the coming years
As aquaculture continues to contribute to the world’s seafood supply, there has been a proportionate rise in dependence on veterinary medicinal products (VMP) used to control disease outbreaks. A wide variety of VMP’S are used in aquaculture settings to control outbreaks of disease and parasites. The incorrect use of VMP’S can lead to rejected shipments, severed contracts, and negative publicity. Risk assessments and management programs must be implemented to assure the supply chain that finished product is not adulterated. Annual third party certification audits are used to gauge compliance with requirements. Globally, large retail chains have committed to purchasing from certified suppliers. This presentation provides a framework for preparing, implementing, and managing the controlled use of VMP’s based on compliance criteria specified in aquaculture certification schemes
#InvitroStudies are critical to the #drug and #wellness product #development due to their ability to provide a basis for #clinical in vivo studies for predicting best delivery model to take Go/No-Go decision. #Our solution on in vitro analyses can provide proof of concept on delivery dosage form in the early stages or reverse pharmacology #development of the active process, when the selectively and possible interactions of the active process, when the selectivity and possible interactions of the candidate drug towards the desired therapeutic target are established. Our team can provide solution map on case to case basis for your specific requirement . For more details please visit on https://www.stabicon.com/In-Vitro.php
Process Analytical Technology, Quality by Design & PharmacogenomicsAjaz Hussain
Keynote address at the 2013 Scientific Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA). The lecture attempts to 'connect the dots' between PAT and QbD to Pharmacogenomics in the context of the authors experience at the US FDA and in industry.
SMi Group announces the return of its 11th annual Pharmaceutical Logistics conference to London on the 18th- 19th May 2017. Outsourcing logistics tasks to third parties has been observed as an emerging trend in the global market and it is only expected to gain momentum in the coming years
As aquaculture continues to contribute to the world’s seafood supply, there has been a proportionate rise in dependence on veterinary medicinal products (VMP) used to control disease outbreaks. A wide variety of VMP’S are used in aquaculture settings to control outbreaks of disease and parasites. The incorrect use of VMP’S can lead to rejected shipments, severed contracts, and negative publicity. Risk assessments and management programs must be implemented to assure the supply chain that finished product is not adulterated. Annual third party certification audits are used to gauge compliance with requirements. Globally, large retail chains have committed to purchasing from certified suppliers. This presentation provides a framework for preparing, implementing, and managing the controlled use of VMP’s based on compliance criteria specified in aquaculture certification schemes
#InvitroStudies are critical to the #drug and #wellness product #development due to their ability to provide a basis for #clinical in vivo studies for predicting best delivery model to take Go/No-Go decision. #Our solution on in vitro analyses can provide proof of concept on delivery dosage form in the early stages or reverse pharmacology #development of the active process, when the selectively and possible interactions of the active process, when the selectivity and possible interactions of the candidate drug towards the desired therapeutic target are established. Our team can provide solution map on case to case basis for your specific requirement . For more details please visit on https://www.stabicon.com/In-Vitro.php
Process Analytical Technology, Quality by Design & PharmacogenomicsAjaz Hussain
Keynote address at the 2013 Scientific Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA). The lecture attempts to 'connect the dots' between PAT and QbD to Pharmacogenomics in the context of the authors experience at the US FDA and in industry.
By choosing Covance as a single, centralized CMC analytical laboratory, you can obtain higher quality analytical data more efficiently and at lower cost/fewer resources than by working with multiple providers/CMOs. This analytical data is the key to knowledge and quality risk management throughout the product lifecycle.
Marv Shepherd, PSM president, Member USP Package Storage and Distribution Expert Committee, and Professor at the University of Texas at Austin speaks about updates to United States Pharmacopeia's good distribution practices.
New requirements for sponsors and laboratories for analyzing clinical trial s...complianceonline123
Learn compliance requirements for clinical laboratories analyzing samples from clinical trials. Understand the compliance requirements concerning ICH GCP for FDA and EMA compliance.
Regulatory Due Diligence, Using Regulatory Affairs to Maximize the Value of a...SGS
Developing a new drug is a costly undertaking, which can cost several hundreds of millions. Except for the largest Pharma companies, any other company will need external funding at some stage in the development of a drug. A solid regulatory strategy in early phase clinical research is essential to convince your investors to further fund the clinical development of your compound. Depending on your compound (chemical, biotech product, advanced therapy) and the type of investors (private investors, government funding bodies or a larger pharmaceutical company), different aspects of the regulatory strategy need to be more developed.
The main aspects of such an early phase regulatory strategy will be discussed and illustrated with a number of case studies such as the development of a regulatory strategy for a bacteriophage and discussions with Health Authorities.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...TGA Australia
TGA Scheduling Working Group Meeting One February 2018. Role of the Working Group including Reforms to the advertising of S3 pharmacist only medicines, Reviewing what current S3 substances should be advertised, Proactively identifying S4 medicine substances for consideration for down-scheduling, Adding a new appendix to the poison standard to provide additional safeguards when down-scheduling
New PDA/IPEC Technical Report on Excipient Risk Assessment - insights for dru...MilliporeSigma
Access the interactive recording: https://bit.ly/37HqbTK
Abstract:
Since March 2016 the EU Guideline to ascertain the appropriate GMP for pharmaceutical excipients is legally binding. Although the EU Guideline itself provides a high level description how to perform the risk assessment, the implementation can be challenging. In January 2018 PDA and IPEC formed a joint Task Force with the objective to develop a joint Technical Report to share best practices with industry. This Technical Report was published in December 2019. In this webinar you will be introduced to the new Technical Report, its objective, proposed approaches and examples shared by PDA/IPEC member companies.
Clinical Trial Supply. GMP meets GCP and GDP. University of CopenhagenSPLY ApS
Master in Drug Development (MIND), Course: "QA, QC, GXP for Pharmaceutical Production". Introduction to Clinical trial supply management, IRT / RTSM systems and drug supply forecasting.
7th Pharmacovigilance 2014 “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" 21st November 2014, Kohinoor Continental Hotel, Mumbai, India Greetings from Virtue Insight, I am happy to invite you and your colleagues to be a sponsor / delegate for our upcoming conference. The “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management” at 7th Pharmacovigilance 2014 on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.Contact:-Tel: +91 9677590192 Email: dinesh@virtueinsight.co.in
Kashf ul Asrar English Book by Hazrat Sultan Bahoo with Original Persian Text
Kashf-ul-Asrar by Sultan-ul-Arifeen Hazrat Sakhi Sultan Bahoo Rehmat-ul-Allah Alayh Translated in English by Mrs. Ambreen Moghees Sarwari Qadri (M.A. Mass Communication) by the permision and supervision of Khadim Sultan-ul-Faqr Hazrat Sakhi Sultan Mohammad Najib-ur-Rehman Sarwari Qadri
For Purchase a Hard Cover Copy kindly Contact
+923454699975
By choosing Covance as a single, centralized CMC analytical laboratory, you can obtain higher quality analytical data more efficiently and at lower cost/fewer resources than by working with multiple providers/CMOs. This analytical data is the key to knowledge and quality risk management throughout the product lifecycle.
Marv Shepherd, PSM president, Member USP Package Storage and Distribution Expert Committee, and Professor at the University of Texas at Austin speaks about updates to United States Pharmacopeia's good distribution practices.
New requirements for sponsors and laboratories for analyzing clinical trial s...complianceonline123
Learn compliance requirements for clinical laboratories analyzing samples from clinical trials. Understand the compliance requirements concerning ICH GCP for FDA and EMA compliance.
Regulatory Due Diligence, Using Regulatory Affairs to Maximize the Value of a...SGS
Developing a new drug is a costly undertaking, which can cost several hundreds of millions. Except for the largest Pharma companies, any other company will need external funding at some stage in the development of a drug. A solid regulatory strategy in early phase clinical research is essential to convince your investors to further fund the clinical development of your compound. Depending on your compound (chemical, biotech product, advanced therapy) and the type of investors (private investors, government funding bodies or a larger pharmaceutical company), different aspects of the regulatory strategy need to be more developed.
The main aspects of such an early phase regulatory strategy will be discussed and illustrated with a number of case studies such as the development of a regulatory strategy for a bacteriophage and discussions with Health Authorities.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...TGA Australia
TGA Scheduling Working Group Meeting One February 2018. Role of the Working Group including Reforms to the advertising of S3 pharmacist only medicines, Reviewing what current S3 substances should be advertised, Proactively identifying S4 medicine substances for consideration for down-scheduling, Adding a new appendix to the poison standard to provide additional safeguards when down-scheduling
New PDA/IPEC Technical Report on Excipient Risk Assessment - insights for dru...MilliporeSigma
Access the interactive recording: https://bit.ly/37HqbTK
Abstract:
Since March 2016 the EU Guideline to ascertain the appropriate GMP for pharmaceutical excipients is legally binding. Although the EU Guideline itself provides a high level description how to perform the risk assessment, the implementation can be challenging. In January 2018 PDA and IPEC formed a joint Task Force with the objective to develop a joint Technical Report to share best practices with industry. This Technical Report was published in December 2019. In this webinar you will be introduced to the new Technical Report, its objective, proposed approaches and examples shared by PDA/IPEC member companies.
Clinical Trial Supply. GMP meets GCP and GDP. University of CopenhagenSPLY ApS
Master in Drug Development (MIND), Course: "QA, QC, GXP for Pharmaceutical Production". Introduction to Clinical trial supply management, IRT / RTSM systems and drug supply forecasting.
7th Pharmacovigilance 2014 “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" 21st November 2014, Kohinoor Continental Hotel, Mumbai, India Greetings from Virtue Insight, I am happy to invite you and your colleagues to be a sponsor / delegate for our upcoming conference. The “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management” at 7th Pharmacovigilance 2014 on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.Contact:-Tel: +91 9677590192 Email: dinesh@virtueinsight.co.in
Kashf ul Asrar English Book by Hazrat Sultan Bahoo with Original Persian Text
Kashf-ul-Asrar by Sultan-ul-Arifeen Hazrat Sakhi Sultan Bahoo Rehmat-ul-Allah Alayh Translated in English by Mrs. Ambreen Moghees Sarwari Qadri (M.A. Mass Communication) by the permision and supervision of Khadim Sultan-ul-Faqr Hazrat Sakhi Sultan Mohammad Najib-ur-Rehman Sarwari Qadri
For Purchase a Hard Cover Copy kindly Contact
+923454699975
MONTHLY DIGITAL KNOCKOUTS
FullSIX’s team wants to share with you every month a selection of the most relevant content on digital media created to inspire and spread
Well, there is hardly a man who would say, ‘I don’t think duct tape can fix that. Since, this sticky silver adhesive tape with durable fabric coating dubbed duct tape is a fix it solution for almost everything from mechanical to packaging.
Rick Pummill - TRPC - Effective Plan Design and AdministrationDowney Brand LLP
In his presentation at the 2015 Savannah Fiduciary Seminar, Rick Pummill of The Retirement Plan Company presented on how to make 401(k) or Defined Contribution Plan operations more effective, from design tips to electronic delivery of disclosures.
Making Value-Based Healthcare in Cataract a Reality Insights from VBHCAT Pr...Alexandre Lourenço
Alexandre Lourenço's keynote on "Making Value-Based Healthcare in Cataract a Reality - Insights from VBHCAT Project in Portugal", at the 44th World Hospital Congress organized by the International Hospital Federation, in November 8th 2021.
IQPC’s Cold Chain MENA summit will combine Supply Chain, Logistics and Quality leaders from Multi-national biopharma companies from the region and around the world as well as government and regulatory figures to discuss issues and proposed solutions that may occur across the supply chain.
For more information, visit www.coldchainmena.com
Point of Care Testing for Enhancing Patient Centered Planned Care DeliveryPAFP
PAFP 2013 Regional Lecture Series
Session 1 - Northeast
Presenter: Linda Thomas-Hemak, MD
The Wright Center for Primary Care
Broadcast live through the PAFP Community.
October 2nd, 2013 12pm - 1pm
SMi Group are thrilled to announce the launch of the Ophthalmic Drugs Conference, being held on the 28-29 November 2017 at the Copthorne Tara Hotel in London, UK. www.ophthalmicdrugs.com/slideshare
OxfordSM's pharma case studies - providing a call to actionOxfordSM
Brand teams have to be increasingly innovative when finding ways to prompt patients and physicians to intervene at the right time.
Campaigns such as GSK’s Greatest Season Ever for FLONASE®, implemented last year in the United States which made the decision to prepare for the allergy season easier for patients by linking the proactive purchase of the brand to the start of the baseball season.
Providing A Call To Action:
We find that examples from within and outside of healthcare can often prompt this innovation. They act as a way of bringing in new perspectives and allowing teams to explore new avenues and new ideas.
So, in the spirit of hoping this will prompt some new ideas in your brand team, here are our favourite case studies that speak to the need to provide a call to action.
Similar to SMi Group's Clinical Trial Logistics 2016 (20)
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
How to Split Bills in the Odoo 17 POS ModuleCeline George
Bills have a main role in point of sale procedure. It will help to track sales, handling payments and giving receipts to customers. Bill splitting also has an important role in POS. For example, If some friends come together for dinner and if they want to divide the bill then it is possible by POS bill splitting. This slide will show how to split bills in odoo 17 POS.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
This is a presentation by Dada Robert in a Your Skill Boost masterclass organised by the Excellence Foundation for South Sudan (EFSS) on Saturday, the 25th and Sunday, the 26th of May 2024.
He discussed the concept of quality improvement, emphasizing its applicability to various aspects of life, including personal, project, and program improvements. He defined quality as doing the right thing at the right time in the right way to achieve the best possible results and discussed the concept of the "gap" between what we know and what we do, and how this gap represents the areas we need to improve. He explained the scientific approach to quality improvement, which involves systematic performance analysis, testing and learning, and implementing change ideas. He also highlighted the importance of client focus and a team approach to quality improvement.
Ethnobotany and Ethnopharmacology:
Ethnobotany in herbal drug evaluation,
Impact of Ethnobotany in traditional medicine,
New development in herbals,
Bio-prospecting tools for drug discovery,
Role of Ethnopharmacology in drug evaluation,
Reverse Pharmacology.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
SMi Group's Clinical Trial Logistics 2016
1. www.clinical-trial-logistics.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 @SMIPHARM
#SMICTL
KEY BENEFITS FOR 2016:
• Gain key regulatory updates from Daiichi Sankyo
and MHRA talking specifically on the development
of the New EU Clinical Trials Regulation
• Discuss how to integrate forecasting and supply
planning to an efficient clinical supply chain with
GlaxoSmithKline
• Norgine presents how they ensure and maintain a
successful contractor relationship
• Engage in discussions with Sanofi on visibility in the
supply chain to fight counterfeiting
SMi Presents the 10th Annual Conference and Exhibition on...
18 -19
MAY
2016
Clinical Trial
Logistics
CHAIR 2016:
Rebecca Jackson, IVR/IWR Manager,
Randomisation & Trial Supply Services, Janssen
FEATURED SPEAKERS:
• Graham McNaughton, Pharmaceutical Assessor,
MHRA
• Elisabetta Carli, Head, Operations Clinical
Vaccines Management, GlaxoSmithKline
• Tony Moult, Director, Clinical Supplies Operations,
Daiichi Sankyo
• Geoffroy Bessaud, AVP, Anti-Counterfeiting
Coordination, Sanofi
• Dawn Padfield, Director of Pharmaceutical
Development and Clinical Supply, Norgine
• Elodie Fontaine, Clinical Trial Lead, Lundbeck
• Jasmin Hellwig, Senior Comparator Specialist,
Merck Sharp and Dohme
• Abdulkareem Ghanayem, Clinical Trial
Operations Project Manager, Takeda
BOOK BY 29TH FEBRUARY AND SAVE £400 | BOOK BY 31ST MARCH AND SAVE £200
Proudly Sponsored By
Holiday Inn Kensington Forum, London, UK
11+ case studies
from international
pharmaceutical
and biotech
companies
Preparing for the journey.
Adapt your CTL within the evolving regulatory
landscape for successful compliance
2. Clinical Trial Logistics
Day One | Wednesday 18th May 2016
08.30 Registration & Coffee
09.00 Chairman's Opening Remarks
Rebecca Jackson, IVR/IWR Manager, Randomisation & Trial
Supply Services, Janssen
OPENING ADDRESS
09.10 Examining the impact of the new Clinical Trials Regulation
(CTR) on industry
•An in depth comparison of the new Clinical Trials
Regulation to the current Clinical Trial Directive
•Assessing the impact of this change to the clinical trial
logistic industry
•Discussing why you should start preparing for this change
now
•The benefits of the CTR towards harmonisation throughout
the EU
•End user perspective on anticipation of future audits
Graham McNaughton, Pharmaceutical Assessor, MHRA
A CLOSER LOOK AT THE CLINICAL SUPPLY CHAIN
09.50 The importance of forecasting and supply planning in
avoiding logistical delays
•Integrating and implementing forecasting and planning
to ensure supply reaches the location in a timely and
safe manner
•How to keep supply planning strategies in line with
increasingly complex clinical trial designs
•A comparison of the different clinical supplies planning
systems
•The role of statistical forecasting in S&OP
Elisabetta Carli, Head, Operations Clinical Vaccines
Management, GlaxoSmithKline
10.30 Morning Coffee
11.00 How to ensure and maintain a successful contractor
relationship
•Implementing due diligence to find the best fit when
choosing a vendor
•The importance of good communication to get the best
out of the relationship
•Negotiating and establishing clear agreements to avoid
logistical pitfalls
•How to retain sufficient control with effective feedback
channels and data monitoring as a client
Dawn Padfield, Director of Pharmaceutical Development
and Clinical Supply, Norgine
11.40 Randomisation and trial supply management (RTSM) or
artificial intelligence (AI)? Human vs. machine in the clinical
supply chain
•Consider the expectations placed on RTSM systems and
vendors in today’s clinical trials
•Evaluate the risk of those expectations to the clinical supply
chain
•The role of the mere human – obsolete or pivotal?
•What does the future of RTSM hold?
Rebecca Jackson, IVR/IWR Manager, Randomisation & Trial
Supply Services, Janssen
12.20 Networking Lunch
13.50 Challenges of operation for paediatric clinical supply
•Investigational Medicinal Products (IMP) – optimizing the
supply chain
•Challenges involved with material supply
•Other challenges not directly related to supplies
Elodie Fontaine, Senior Clinical Operations Leader, Lundbeck
14.30 GS1 standards – for improved patient care and supply chain
efficiency
•Global standards – why are they needed?
•GS1 system of standards – Identify, capture and share
•Worldwide regulatory developments
•The benefit and ROI of global standards
Ulrike Kreysa, Vice-President Healthcare, GS1 Global Office
15.10 Afternoon Tea
THE ONGOING CHALLENGE OF TEMPERATURE CONTROL
15.40 Challenges in air-freighting time & temperature shipments
•What are the potential risk points for air-freight?
•How does IATA Ch.17 Regulations improve the handling
and risk mitigation of clinical trial shipments?
•What has been the impact of GDP for airlines?
•How do airlines maximise performance delivery?
Alan Dorling, Global Head - Pharmaceuticals & Life
Sciences, IAG Cargo
KEYNOTE PRESENTATION
16.20 Temperature excursion management
•Challenges that occur during shipment to sites and during
storage at site.
•How to manage temperature excursion
•IRT as a supportive tool
•Predicting the risk
Alexandra Tsioni, Manager, Clinical Supply Chain Study
Lead, Global Clinical Operations, Teva Israel
THE IMPORTANCE OF LABELLING
17.00 EU CTR Annex VI: Labelling of investigational medicinal
products (IMPs)
•CTR timing with respect to labels on IMPs
•Examining the increased complexity of packaging and
labelling of investigational medicinal products
•Understanding what information must be included on
labels
•How to deal with this change and what process should be
implemented to ease adherence
•The current status of the Industry efforts to have Annex VI
changed
Tony Moult, Director, Clinical Supplies Operations,
Daiichi Sankyo
17.40 Chairman’s Closing Remarks and Close of Day One
Rebecca Jackson, IVR/IWR Manager, Randomisation & Trial
Supply Services, Janssen
Register online at: www.clinical-trial-logistics.com • Alternatively fa
Sponsored by
FedEx Express is the world's largest express transportation
company, providing fast and reliable delivery to more
than 220 countries and territories. FedEx Express uses a
global air-and-ground network to speed delivery of
time-sensitive shipments, by a definite time and date
with a money-back guarantee. For more information visit
www.fedex.com/gb
Official Media Partners
3. Clinical Trial Logistics
Day Two | Thursday 19th May 2016
08.30 Registration & Coffee
09.00 Chairman's Opening Remarks
Rebecca Jackson, IVR/IWR Manager, Randomisation & Trial
Supply Services, Janssen
OPENING ADDRESS
09.10 Update to ICH GCP E6 (R2)
•Analysis and understanding the proposed changes
•What are the key changes
•What are the implications of the changes
Amer Alghabban, Vice President GxP Quality Assurance,
Compliance & Training, Karyopharm Therapeutics Inc.
09.50 GDP: Gaps discovered and prioritised case study
- a risk-based approach to the EU GDP guidelines
•The challenges of transporting clinical trials across the globe
•Are we doing enough to comply with the regulations?
•Identifying the gaps, assessing the risks prioritising corrective
actions – case Study
Sanjay Nadarajah, Quality Director, Inglasia Pharma Solutions
10.30 Morning Coffee
11.00 Understanding the impact of the EU GDP guidelines
•Examining industries approach to GDP in the supply chain
•How to effectively adhere to the guidelines
•Current supply chain capability – available services,
resources and monitoring
Amy Shortmann, Consultant, Director, ASC Associates Ltd
IMPLEMENTING A STRINGENT CLINICAL TRIAL LOGISTICS STRATEGY
11.40 Visibility in the supply chain to fight counterfeiting
•Examining the issue of counterfeiting
•How to implement supply chain visibility and security
•Traceability requirements worldwide
Geoffroy Bessaud, Associate Vice President,
Anti-Counterfeiting Coordination, Sanofi
12.20 Networking Lunch
13.50 Panel Discussion: The Falsified Medicine Directive
•Challenges faced with complying with the
Falsified Medicines Directive
•The role of the national medicines verification
organisation (NMVO)
•Implementation of the the unique identifier
Panelists
Geoffroy Bessaud, Associate Vice President,
Anti-Counterfeiting Coordination, Sanofi
Amer Alghabban, Vice President GxP Quality Assurance,
Compliance & Training, Karyopharm Therapeutics Inc.
Ulrike Kreysa, Vice-President Healthcare, GS1 Global Office
SUPPLY CHAIN STRATEGY & EMERGING MARKETS
14.30 Comparators in clinical trials: Effective meets flexible supply
chain
•How to match supply and demand? Demand planning view
•How to match supply and demand? Comparator sourcing
activities
•Handling comparator related operational challenges
Jasmin Hellwig, Senior, Comparator Specialist, Merck Sharp
and Dohme
15.10 Afternoon Tea
KEYNOTE PRESENTATION
15.40 Implementing a compliant and patient centric clinical
supply strategy
•Incorporating compliance changes and regulatory
updates in to your strategy
•Planning a patient centric strategy with a focus on
patient shipments
•Incorporating patient needs in to the supply chain
throughout
Rocio Cuadrado, TSOM Leader Clinical Supplies SCP
– Studies & Distribution, Sanofi
16.20 Clinical trial supply challenges in the Middle East
•Dealing with local customs and cultures
•How to deal with multiple regulatory environments
•Opportunities and challenges
Abdulkareem Ghanayem, Clinical Trial Operations Project
Manager, Takeda
17.00 The planning phase: Phase I, biological products
•Focus on limited amount of drug, on-going accelerated
stability and the impact on the expiry of the drug
•Pros and cons when using CMOs and CROs
•Ordering of IMP with special requirements to ensure only a
limited group of people handling the drug
•Shipment requirements including decision to use
warehouses or ship directly to sites within 2-8 °C all over the
world
Lis Hansen, Clinical Trial Supply Coordinator, Genmab A/S
17.40 Chairman’s Closing Remarks and Close of Day Two
Rebecca Jackson, IVR/IWR Manager, Randomisation & Trial
Supply Services, Janssen
Supported by
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Honey De Gracia, SMi Marketing on +44 (0) 207 827 6102 or email: hdegracia@smi-online.co.uk
ax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
4. FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
CLINICAL TRIAL LOGISTICS
Conference: Wednesday 18th & Thursday 19th May 2016, Holiday Inn Kensington Forum, London, UK
4 WAYS TO REGISTER
www.clinical-trial-logistics.com
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
Unique Reference Number
Our Reference LVP-173
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 29th February 2016 to receive £400 off the conference price
□ Book by 31st March 2016 to receive £200 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-173 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on
Document portal and literature distribution for all UK customers and for those EU Customers
not supplying a registration number for their own country here.
______________________________________________________________________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference only £1499.00 + VAT £1798.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the
Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.